Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 447

1.

Extemporaneous Preparation of Injectable and Enzymatically Degradable 3D Cell Culture Matrices from an Animal-Component-Free Recombinant Protein Based on Human Collagen Type I.

Kamata H, Ashikari-Hada S, Mori Y, Azuma A, Hata KI.

Macromol Rapid Commun. 2019 May 28:e1900127. doi: 10.1002/marc.201900127. [Epub ahead of print]

PMID:
31136037
2.

Analysis of the Genetic Diversity and Structure of the Grey-Faced Buzzard (Butastur indicus) in Japan, Based on mtDNA.

Nagai K, Iseki F, Azuma A.

Zoolog Sci. 2019 Feb;36(1):17-22. doi: 10.2108/zs180077.

PMID:
31116534
3.

Nintedanib for Systemic Sclerosis-Associated Interstitial Lung Disease.

Distler O, Highland KB, Gahlemann M, Azuma A, Fischer A, Mayes MD, Raghu G, Sauter W, Girard M, Alves M, Clerisme-Beaty E, Stowasser S, Tetzlaff K, Kuwana M, Maher TM; SENSCIS Trial Investigators.

N Engl J Med. 2019 May 20. doi: 10.1056/NEJMoa1903076. [Epub ahead of print]

PMID:
31112379
4.

A case of severe pneumonitis with alveolar hemorrhage associated with herbal medicines.

Omori M, Saito Y, Miura Y, Tanaka T, Kashiwada T, Atsumi K, Hayashi H, Minegishi Y, Fujita K, Azuma A, Seike M, Gemma A.

J Nippon Med Sch. 2019 May 17. doi: 10.1272/jnms.JNMS.2019_86-504. [Epub ahead of print]

5.

Activated Fibroblast Program Orchestrates Tumor Initiation and Progression; Molecular Mechanisms and the Associated Therapeutic Strategies.

Yoshida GJ, Azuma A, Miura Y, Orimo A.

Int J Mol Sci. 2019 May 7;20(9). pii: E2256. doi: 10.3390/ijms20092256. Review.

6.

Criteria for the diagnosis of idiopathic pleuroparenchymal fibroelastosis: A proposal.

Watanabe K, Ishii H, Kiyomi F, Terasaki Y, Hebisawa A, Kawabata Y, Johkoh T, Sakai F, Kondoh Y, Inoue Y, Azuma A, Suda T, Ogura T, Inase N, Homma S; Study Group on Diffuse Pulmonary Disorders, Scientific Research/Research on Intractable Diseases in Japan.

Respir Investig. 2019 Apr 10. pii: S2212-5345(18)30258-2. doi: 10.1016/j.resinv.2019.02.007. [Epub ahead of print] Review.

PMID:
30981683
7.

Lung function outcomes in the INPULSIS® trials of nintedanib in idiopathic pulmonary fibrosis.

Brown KK, Flaherty KR, Cottin V, Raghu G, Inoue Y, Azuma A, Huggins JT, Richeldi L, Stowasser S, Stansen W, Schlenker-Herceg R, Maher TM, Wells AU.

Respir Med. 2019 Jan;146:42-48. doi: 10.1016/j.rmed.2018.11.012. Epub 2018 Nov 19.

PMID:
30665517
8.

Therapeutic effects of nintedanib are not influenced by emphysema in the INPULSIS trials.

Cottin V, Azuma A, Raghu G, Stansen W, Stowasser S, Schlenker-Herceg R, Kolb M.

Eur Respir J. 2019 Apr 18;53(4). pii: 1801655. doi: 10.1183/13993003.01655-2018. Print 2019 Apr. No abstract available.

PMID:
30655282
9.

Long-term safety of pirfenidone: results of the prospective, observational PASSPORT study.

Cottin V, Koschel D, Günther A, Albera C, Azuma A, Sköld CM, Tomassetti S, Hormel P, Stauffer JL, Strombom I, Kirchgaessler KU, Maher TM.

ERJ Open Res. 2018 Oct 19;4(4). pii: 00084-2018. doi: 10.1183/23120541.00084-2018. eCollection 2018 Oct.

10.

An on-site preparable, novel bone-grafting complex consisting of human platelet-rich fibrin and porous particles made of a recombinant collagen-like protein.

Tsukioka T, Hiratsuka T, Nakamura M, Watanabe T, Kitamura Y, Isobe K, Okudera T, Okudera H, Azuma A, Uematsu K, Nakata K, Kawase T.

J Biomed Mater Res B Appl Biomater. 2019 Jul;107(5):1420-1430. doi: 10.1002/jbm.b.34234. Epub 2018 Oct 1.

PMID:
30270545
11.

Diagnosis of Idiopathic Pulmonary Fibrosis. An Official ATS/ERS/JRS/ALAT Clinical Practice Guideline.

Raghu G, Remy-Jardin M, Myers JL, Richeldi L, Ryerson CJ, Lederer DJ, Behr J, Cottin V, Danoff SK, Morell F, Flaherty KR, Wells A, Martinez FJ, Azuma A, Bice TJ, Bouros D, Brown KK, Collard HR, Duggal A, Galvin L, Inoue Y, Jenkins RG, Johkoh T, Kazerooni EA, Kitaichi M, Knight SL, Mansour G, Nicholson AG, Pipavath SNJ, Buendía-Roldán I, Selman M, Travis WD, Walsh S, Wilson KC; American Thoracic Society, European Respiratory Society, Japanese Respiratory Society, and Latin American Thoracic Society.

Am J Respir Crit Care Med. 2018 Sep 1;198(5):e44-e68. doi: 10.1164/rccm.201807-1255ST.

PMID:
30168753
12.

Cytometrical analysis of the adverse effects of indican, indoxyl, indigo, and indirubin on rat thymic lymphocytes.

Funakoshi Y, Azuma A, Ishikawa M, Itsuki S, Tamura Y, Kanemaru K, Hirai S, Oyama Y.

Toxicol Res (Camb). 2018 Mar 28;7(3):513-520. doi: 10.1039/c7tx00244k. eCollection 2018 May 8.

13.

Diffuse panbronchiolitis: A fine road from the discovery of a disease to the establishment of treatment.

Kamio K, Azuma A.

Respir Investig. 2018 Sep;56(5):373-374. doi: 10.1016/j.resinv.2018.07.001. Epub 2018 Jul 23. No abstract available.

PMID:
30049592
14.

Japanese guideline for the treatment of idiopathic pulmonary fibrosis.

Homma S, Bando M, Azuma A, Sakamoto S, Sugino K, Ishii Y, Izumi S, Inase N, Inoue Y, Ebina M, Ogura T, Kishi K, Kishaba T, Kido T, Gemma A, Goto Y, Sasaki S, Johkoh T, Suda T, Takahashi K, Takahashi H, Taguchi Y, Date H, Taniguchi H, Nakayama T, Nishioka Y, Hasegawa Y, Hattori N, Fukuoka J, Miyamoto A, Mukae H, Yokoyama A, Yoshino I, Watanabe K; Ministry of Health, Labour and Welfare, the Study Group on Diffuse Pulmonary Disorders, Scientific Research/Research on Intractable Diseases, and Japanese Respiratory Society.

Respir Investig. 2018 Jul;56(4):268-291. doi: 10.1016/j.resinv.2018.03.003. Epub 2018 Jul 3. Review.

PMID:
29980444
15.

Prognostic significance of ventricular late potentials in patients with pulmonary sarcoidosis.

Yodogawa K, Seino Y, Ohara T, Iwasaki YK, Hayashi M, Miyauchi Y, Azuma A, Shimizu W.

Heart Rhythm. 2018 Jun;15(6):798-802. doi: 10.1016/j.hrthm.2018.03.013.

PMID:
29857850
16.

Resolution of bleomycin-induced murine pulmonary fibrosis via a splenic lymphocyte subpopulation.

Kamio K, Azuma A, Matsuda K, Usuki J, Inomata M, Morinaga A, Kashiwada T, Nishijima N, Itakura S, Kokuho N, Atsumi K, Hayashi H, Yamaguchi T, Fujita K, Saito Y, Abe S, Kubota K, Gemma A.

Respir Res. 2018 Apr 24;19(1):71. doi: 10.1186/s12931-018-0783-2.

17.

A Community-Level Initiative to Prevent Obesity: Results From Kaiser Permanente's Healthy Eating Active Living Zones Initiative in California.

Cheadle A, Atiedu A, Rauzon S, Schwartz PM, Keene L, Davoudi M, Spring R, Molina M, Lee L, Boyle K, Williamson D, Steimberg C, Tinajero R, Ravel J, Nudelman J, Azuma AM, Kuo ES, Solomon L.

Am J Prev Med. 2018 May;54(5S2):S150-S159. doi: 10.1016/j.amepre.2018.01.024.

18.

Reduced incidence of lung cancer in patients with idiopathic pulmonary fibrosis treated with pirfenidone.

Miura Y, Saito T, Tanaka T, Takoi H, Yatagai Y, Inomata M, Nei T, Saito Y, Gemma A, Azuma A.

Respir Investig. 2018 Jan;56(1):72-79. doi: 10.1016/j.resinv.2017.09.007. Epub 2017 Oct 25.

PMID:
29325685
19.

Prognostic Factors in the Acute Exacerbation of Idiopathic Pulmonary Fibrosis: A Retrospective Single-center Study.

Atsumi K, Saito Y, Kuse N, Kobayashi K, Tanaka T, Kashiwada T, Inomata M, Kokuho N, Hayashi H, Kamio K, Fujita K, Abe S, Azuma A, Kubota K, Gemma A.

Intern Med. 2018 Mar 1;57(5):655-661. doi: 10.2169/internalmedicine.9331-17. Epub 2017 Nov 20.

20.

CRISPR/Cas9-mediated targeted mutagenesis in grape.

Nakajima I, Ban Y, Azuma A, Onoue N, Moriguchi T, Yamamoto T, Toki S, Endo M.

PLoS One. 2017 May 18;12(5):e0177966. doi: 10.1371/journal.pone.0177966. eCollection 2017.

21.

Cyclic mechanical stretch-induced oxidative stress occurs via a NOX-dependent mechanism in type II alveolar epithelial cells.

Tanaka T, Saito Y, Matsuda K, Kamio K, Abe S, Kubota K, Azuma A, Gemma A.

Respir Physiol Neurobiol. 2017 Aug;242:108-116. doi: 10.1016/j.resp.2017.04.007. Epub 2017 Apr 22.

PMID:
28442445
22.

Granuloma-forming interstitial pneumonia induced by nivolumab: a possible immune-related adverse event of the lung.

Kashiwada T, Saito Y, Minegishi Y, Kokuho N, Takahashi A, Takahashi S, Atsumi K, Seike M, Azuma A, Kubota K, Terasaki Y, Gemma A.

Int Cancer Conf J. 2017 Apr 4;6(3):131-134. doi: 10.1007/s13691-017-0291-0. eCollection 2017 Jul.

23.

XPLN is modulated by HDAC inhibitors and negatively regulates SPARC expression by targeting mTORC2 in human lung fibroblasts.

Kamio K, Azuma A, Usuki J, Matsuda K, Inomata M, Nishijima N, Itakura S, Hayashi H, Kashiwada T, Kokuho N, Atsumi K, Yamaguchi T, Fujita K, Saito Y, Abe S, Kubota K, Gemma A.

Pulm Pharmacol Ther. 2017 Jun;44:61-69. doi: 10.1016/j.pupt.2017.03.003. Epub 2017 Mar 14.

PMID:
28315487
24.

Nrf2 Regulates the Risk of a Diesel Exhaust Inhalation-Induced Immune Response during Bleomycin Lung Injury and Fibrosis in Mice.

Li YJ, Shimizu T, Shinkai Y, Hirata Y, Inagaki H, Takeda K, Azuma A, Yamamoto M, Kawada T.

Int J Mol Sci. 2017 Mar 17;18(3). pii: E649. doi: 10.3390/ijms18030649.

25.

Safety management of treatment with nintedanib in clinical practice of IPF.

Azuma A.

Respir Investig. 2017 Jan;55(1):1. doi: 10.1016/j.resinv.2016.12.001. No abstract available.

26.

Nintedanib in Japanese patients with idiopathic pulmonary fibrosis: A subgroup analysis of the INPULSIS® randomized trials.

Azuma A, Taniguchi H, Inoue Y, Kondoh Y, Ogura T, Homma S, Fujimoto T, Sakamoto W, Sugiyama Y, Nukiwa T.

Respirology. 2017 May;22(4):750-757. doi: 10.1111/resp.12960. Epub 2016 Dec 20.

PMID:
27997064
27.

Idiopathic Pulmonary Fibrosis: Treatment and Prognosis.

Fujimoto H, Kobayashi T, Azuma A.

Clin Med Insights Circ Respir Pulm Med. 2016 Dec 8;9(Suppl 1):179-185. eCollection 2015. Review.

28.

An exploratory trial of intravenous immunoglobulin therapy for idiopathic pulmonary fibrosis: a preliminary multicenter report.

Enomoto N, Chida K, Suda T, Kaida Y, Taniguchi M, Azuma A, Hayashi H, Ogura T, Kitamura H, Yamaguchi O, Ando M, Sato A, Kudo S.

Clin Respir J. 2016 Nov;10(6):746-755. doi: 10.1111/crj.12281. Epub 2015 Mar 19.

PMID:
25689162
29.

Pirfenidone exerts a suppressive effect on CCL18 expression in U937-derived macrophages partly by inhibiting STAT6 phosphorylation.

Saito Y, Azuma A, Matsuda K, Kamio K, Abe S, Gemma A.

Immunopharmacol Immunotoxicol. 2016 Dec;38(6):464-471. doi: 10.1080/08923973.2016.1247852. Epub 2016 Oct 27.

PMID:
27788604
30.

Long-term efficacy of macrolide treatment in idiopathic pulmonary fibrosis: a retrospective analysis.

Kuse N, Abe S, Hayashi H, Kamio K, Saito Y, Usuki J, Azuma A, Kudoh S, Gemma A.

Sarcoidosis Vasc Diffuse Lung Dis. 2016 Oct 7;33(3):242-246.

PMID:
27758989
31.

The photomorphogenic factors UV-B RECEPTOR 1, ELONGATED HYPOCOTYL 5, and HY5 HOMOLOGUE are part of the UV-B signalling pathway in grapevine and mediate flavonol accumulation in response to the environment.

Loyola R, Herrera D, Mas A, Wong DC, Höll J, Cavallini E, Amato A, Azuma A, Ziegler T, Aquea F, Castellarin SD, Bogs J, Tornielli GB, Peña-Neira A, Czemmel S, Alcalde JA, Matus JT, Arce-Johnson P.

J Exp Bot. 2016 Oct;67(18):5429-5445. Epub 2016 Aug 19.

32.

A phase II trial evaluating the efficacy and safety of perioperative pirfenidone for prevention of acute exacerbation of idiopathic pulmonary fibrosis in lung cancer patients undergoing pulmonary resection: West Japan Oncology Group 6711 L (PEOPLE Study).

Iwata T, Yoshino I, Yoshida S, Ikeda N, Tsuboi M, Asato Y, Katakami N, Sakamoto K, Yamashita Y, Okami J, Mitsudomi T, Yamashita M, Yokouchi H, Okubo K, Okada M, Takenoyama M, Chida M, Tomii K, Matsuura M, Azuma A, Iwasawa T, Kuwano K, Sakai S, Hiroshima K, Fukuoka J, Yoshimura K, Tada H, Nakagawa K, Nakanishi Y; West Japan Oncology Group.

Respir Res. 2016 Jul 22;17(1):90. doi: 10.1186/s12931-016-0398-4.

33.

Subgroup analysis of Asian patients in the INPULSIS® trials of nintedanib in idiopathic pulmonary fibrosis.

Taniguchi H, Xu Z, Azuma A, Inoue Y, Li H, Fujimoto T, Bailes Z, Schlenker-Herceg R, Kim DS.

Respirology. 2016 Nov;21(8):1425-1430. doi: 10.1111/resp.12852. Epub 2016 Jul 11.

34.

Cytotoxic actions of 2,2-dibromo-3-nitrilopropionamide, a biocide in hydraulic fracturing fluids, on rat thymocytes.

Ishikawa M, Muraguchi R, Azuma A, Nawata S, Miya M, Katsuura T, Naito T, Oyama Y.

Toxicol Res (Camb). 2016 Jun 21;5(5):1329-1334. doi: 10.1039/c6tx00027d. eCollection 2016 Sep 1.

35.

[The Latest Information on Respiratory Disease Management. Topics: III. New Treatment of Idiopathic Pulmonary Fibrosis].

Kashiwada T, Azuma A.

Nihon Naika Gakkai Zasshi. 2016 Jun;105(6):970-6. Japanese. No abstract available.

PMID:
30168687
36.

Context Dependent Effect of Landscape on the Occurrence of an Apex Predator across Different Climate Regions.

Fujita G, Azuma A, Nonaka J, Sakai Y, Sakai H, Iseki F, Itaya H, Fukasawa K, Miyashita T.

PLoS One. 2016 Apr 28;11(4):e0153722. doi: 10.1371/journal.pone.0153722. eCollection 2016.

37.

COPD advances in left ventricular diastolic dysfunction.

Kubota Y, Asai K, Murai K, Tsukada YT, Hayashi H, Saito Y, Azuma A, Gemma A, Shimizu W.

Int J Chron Obstruct Pulmon Dis. 2016 Mar 29;11:649-55. doi: 10.2147/COPD.S101082. eCollection 2016.

38.

Pulmonary mucosa-associated lymphoid tissue lymphoma associated with pulmonary sarcoidosis: a case report and literature review.

Kokuho N, Terasaki Y, Urushiyama H, Terasaki M, Kunugi S, Morimoto T, Azuma A, Usuda J, Gemma A, Eishi Y, Shimizu A.

Hum Pathol. 2016 May;51:57-63. doi: 10.1016/j.humpath.2015.12.019. Epub 2016 Jan 14. Review.

PMID:
27067783
39.

An efficient method for the preparation of preferentially heterodimerized recombinant S100A8/A9 coexpressed in Escherichia coli.

Futami J, Atago Y, Azuma A, Putranto EW, Kinoshita R, Murata H, Sakaguchi M.

Biochem Biophys Rep. 2016 Mar 19;6:94-100. doi: 10.1016/j.bbrep.2016.03.009. eCollection 2016 Jul.

40.

Clinical Experience of the Long-term Use of Pirfenidone for Idiopathic Pulmonary Fibrosis.

Bando M, Yamauchi H, Ogura T, Taniguchi H, Watanabe K, Azuma A, Homma S, Sugiyama Y; Japan Pirfenidone Clinical Study Group.

Intern Med. 2016;55(5):443-8. doi: 10.2169/internalmedicine.55.5272. Epub 2016 Mar 1.

41.

Variants near the HLA complex group 22 gene (HCG22) confer increased susceptibility to late-onset asthma in Japanese populations.

Yatagai Y, Hirota T, Sakamoto T, Yamada H, Masuko H, Kaneko Y, Iijima H, Naito T, Noguchi E, Tamari M, Kubo M, Takahashi A, Konno S, Makita H, Nishimura M, Hijikata M, Keicho N, Homma S, Taguchi Y, Azuma A, Kudoh S, Hizawa N.

J Allergy Clin Immunol. 2016 Jul;138(1):281-283.e13. doi: 10.1016/j.jaci.2015.11.023. Epub 2016 Jan 30. No abstract available.

PMID:
26830115
42.

Cyclosporine A combined with low-dose corticosteroid treatment in patients with idiopathic pulmonary fibrosis.

Miyazaki Y, Azuma A, Inase N, Taniguchi H, Ogura T, Inoue E, Takeuchi M, Yoshizawa Y, Sugiyama Y, Kudoh S; IPF trial group in Japan.

Respir Investig. 2015 Nov;53(6):288-95. doi: 10.1016/j.resinv.2015.05.002. Epub 2015 Jul 14.

PMID:
26521106
43.

Efficacy of pirfenidone and disease severity of idiopathic pulmonary fibrosis: Extended analysis of phase III trial in Japan.

Taguchi Y, Ebina M, Hashimoto S, Ogura T, Azuma A, Taniguchi H, Kondoh Y, Suga M, Takahashi H, Nakata K, Sugiyama Y, Kudoh S, Nukiwa T; Pirfenidone Clinical Study Group in Japan.

Respir Investig. 2015 Nov;53(6):279-87. doi: 10.1016/j.resinv.2015.06.002. Epub 2015 Oct 23.

PMID:
26521105
44.

Risk factors for acute exacerbation of idiopathic pulmonary fibrosis--Extended analysis of pirfenidone trial in Japan.

Kondoh Y, Taniguchi H, Ebina M, Azuma A, Ogura T, Taguchi Y, Suga M, Takahashi H, Nakata K, Sugiyama Y, Kudoh S, Nukiwa T.

Respir Investig. 2015 Nov;53(6):271-8. doi: 10.1016/j.resinv.2015.04.005. Epub 2015 Aug 4.

PMID:
26521104
45.

Efficacy of Nintedanib in Idiopathic Pulmonary Fibrosis across Prespecified Subgroups in INPULSIS.

Costabel U, Inoue Y, Richeldi L, Collard HR, Tschoepe I, Stowasser S, Azuma A.

Am J Respir Crit Care Med. 2016 Jan 15;193(2):178-85. doi: 10.1164/rccm.201503-0562OC.

PMID:
26393389
46.

Nintedanib: evidence for its therapeutic potential in idiopathic pulmonary fibrosis.

Inomata M, Nishioka Y, Azuma A.

Core Evid. 2015 Aug 27;10:89-98. doi: 10.2147/CE.S82905. eCollection 2015. Review.

47.

All-case post-marketing surveillance of 1371 patients treated with pirfenidone for idiopathic pulmonary fibrosis.

Ogura T, Azuma A, Inoue Y, Taniguchi H, Chida K, Bando M, Niimi Y, Kakutani S, Suga M, Sugiyama Y, Kudoh S, Nukiwa T.

Respir Investig. 2015 Sep;53(5):232-41. doi: 10.1016/j.resinv.2015.06.001. Epub 2015 Aug 17.

PMID:
26344613
48.

An Official ATS/ERS/JRS/ALAT Clinical Practice Guideline: Treatment of Idiopathic Pulmonary Fibrosis. An Update of the 2011 Clinical Practice Guideline.

Raghu G, Rochwerg B, Zhang Y, Garcia CA, Azuma A, Behr J, Brozek JL, Collard HR, Cunningham W, Homma S, Johkoh T, Martinez FJ, Myers J, Protzko SL, Richeldi L, Rind D, Selman M, Theodore A, Wells AU, Hoogsteden H, Schünemann HJ; American Thoracic Society; European Respiratory society; Japanese Respiratory Society; Latin American Thoracic Association.

Am J Respir Crit Care Med. 2015 Jul 15;192(2):e3-19. doi: 10.1164/rccm.201506-1063ST. Erratum in: Am J Respir Crit Care Med. 2015 Sep 1;192(5):644. Dosage error in article text.

PMID:
26177183
49.

Evaluation of microelement contents in Clethra barbinervis as food for human and animals in contrasting geological areas.

Azuma AK, Tomioka R, Takenaka C.

Environ Geochem Health. 2016 Apr;38(2):437-48. doi: 10.1007/s10653-015-9731-y. Epub 2015 Jun 29.

PMID:
26119806
50.

Nintedanib modulates surfactant protein-D expression in A549 human lung epithelial cells via the c-Jun N-terminal kinase-activator protein-1 pathway.

Kamio K, Usuki J, Azuma A, Matsuda K, Ishii T, Inomata M, Hayashi H, Kokuho N, Fujita K, Saito Y, Miya T, Gemma A.

Pulm Pharmacol Ther. 2015 Jun;32:29-36. doi: 10.1016/j.pupt.2015.03.001. Epub 2015 Apr 2.

PMID:
25843005

Supplemental Content

Support Center